Ischaemic cardiovascular risk with allopurinol and protective effect of colchicine in gout: a Dutch nationwide pharmaco-epidemiological study
Allopurinol initiation was associated with a substantial and dose-dependent increase in CVD risk in gout patients, especially in the first 30-90 days and at dosages ≥300 mg/day. Concomitant colchicine use reduced this risk. Discontinuation of allopurinol was not associated with CVD risk.
Authors
- Noortje van Herwaarden (ORCID: https://orcid.org/0000-0002-9527-851X)
- Alfons A den Broeder (ORCID: https://orcid.org/0000-0002-9012-4079)
- M. Opdam (ORCID: https://orcid.org/0000-0003-3385-8807)
- Maike H M Wientjes (ORCID: https://orcid.org/0000-0002-6666-9378)
- Dina Vojinović (ORCID: https://orcid.org/0000-0001-5744-0232)
- Leo A. B. Joosten (ORCID: https://orcid.org/0000-0001-6166-9830)
- Isla S. Mackenzie (ORCID: https://orcid.org/0000-0002-3680-7127)
- Bas Schouwenberg
- Iris Rose Peeters (ORCID: https://orcid.org/0000-0002-7991-6112)
- Marcel Flendrie (ORCID: https://orcid.org/0000-0001-9944-4389)
- Kayleigh M van de Wiel
- Călin D. Popa (ORCID: https://orcid.org/0000-0001-9470-9720)
- Martijn Gerritsen (ORCID: https://orcid.org/0009-0007-0634-695X)
Institutions
- Radboud University Nijmegen (NL)
- University of Dundee (GB)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Radboud University Medical Center (NL)
- IQVIA (United Kingdom) (GB)
- Reade (NL)
- Radboud Institute for Molecular Life Sciences (NL)
- Sint Maartenskliniek (NL)
- Sint Maartenskliniek (NL)
- IQ Solutions (US)
- Center for Rheumatology (US)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1093/eurjpc/zwaf513
- Citations
- 2
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 2.86